Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full-year 2025 results: About UZEDY ® 2025 net sales reached $191 million, including $55 million in the fourth quarter Teva's initial 2026 net sales outlook is in the range of $250 - $280 million Medincell receives mid-to high-single-digit royalties on UZEDY ® net sales and is eligible for up to $105 million in commercial milestone payments, subject to the achievement of annual sales thresholds. About OLANZAPINE LAI Olanzapine Long-Acting Injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation for a broad population of patients living with schizophrenia. Submission of Olanzapine LAI in the European Union for the treatment of schizophrenia in adults is expected in Q2 2026 Following submission to the European Medicines Agency (EMA), regulatory review process begins with
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Is Teva Pharmaceutical Industries Limited (TEVA) an Undervalued Stock Relative to Its Long-Term Potential? [Yahoo! Finance]Yahoo! Finance
- Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis [Yahoo! Finance]Yahoo! Finance
- Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 2/3/26 - Form 10-K
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- TEVA's page on the SEC website